The Source Blog
Recent Action in Pharmaceuticals
Mo. Rev. Stat. §§ 376.1350 through 376.1389: Health Care Utilization Review – Missouri
Introduced: Status: Enacted
A utilization review program shall use documented clinical review criteria that are based on sound clinical evidence and are evaluated periodically to assure ongoing efficacy. A health carrier may develop its own clinical review criteria, […]
Download
Cal. Health & Safety Code §§ 127675 through 127686: Prescription Drug Pricing for Purchasers – California
Introduced: Status: Enacted
It is the intent of the Legislature in enacting this chapter to provide notice and disclosure of information relating to the cost and pricing of prescription drugs in order to provide accountability to the state […]
Download
Tex. Occ. Code §§ 157.051 through 157.060: Physicians– Authority of Physician to Delegate Certain Medical Acts – Texas
Introduced: Status: Enacted
A physician may delegate to an advanced practice registered nurse or physician assistant, acting under adequate physician supervision, the act of prescribing or ordering a drug or device as authorized through a prescriptive authority agreement.
Download
Or. Rev. Stat. §§ 743B.250 through 743B.258: Health Benefit Plans: Individual and Group — Grievances and Appeals – Oregon
Introduced: Status: Enacted
Provides the process for appeal and external review. Requires an insurer to provide all information relating to benefit design and provider networks. States that an insurer must have an external review program to assess whether […]
Download
Or. Rev. Stat. § 743A.082. Diabetes management for pregnant women: Health Insurance: Reimbursement of Claims – Oregon
Introduced: Status: Enacted
States that a health benefit plan may not require a copayment or impose a coinsurance requirement or deductible on the covered services, medications and supplies that are medically necessary for a woman to manage her […]
Download
Or. Rev. Stat. §§ 743.028 through 743.035: Health and Life Insurance — General Provisions (Forms and Standards) – Oregon
Introduced: Status: Enacted
The Department of Consumer and Business Services, in consultation with the Oregon Health Authority, shall develop by rule a form that providers in this state shall use to request prior authorization for prescription drug benefits.
Download
Or. Rev. Stat. § 678.390. Authority of nurse practitioner and clinical nurse specialist to write prescriptions or dispense drugs; notice; requirements; revocation; rules: Professional Nurses (Prescriptive Authority) – Oregon
Introduced: Status: Enacted
The Oregon State Board of Nursing may authorize a certified nurse practitioner or certified clinical nurse specialist to write prescriptions, including prescriptions for controlled substances listed in schedules II, III, III N, IV and V.
Download
Next | See all Legislation Records
Introduced: Status: Enacted
A utilization review program shall use documented clinical review criteria that are based on sound clinical evidence and are evaluated periodically to assure ongoing efficacy. A health carrier may develop its own clinical review criteria, […]
Download
Cal. Health & Safety Code §§ 127675 through 127686: Prescription Drug Pricing for Purchasers – California
Introduced: Status: Enacted
It is the intent of the Legislature in enacting this chapter to provide notice and disclosure of information relating to the cost and pricing of prescription drugs in order to provide accountability to the state […]
Download
Tex. Occ. Code §§ 157.051 through 157.060: Physicians– Authority of Physician to Delegate Certain Medical Acts – Texas
Introduced: Status: Enacted
A physician may delegate to an advanced practice registered nurse or physician assistant, acting under adequate physician supervision, the act of prescribing or ordering a drug or device as authorized through a prescriptive authority agreement.
Download
Or. Rev. Stat. §§ 743B.250 through 743B.258: Health Benefit Plans: Individual and Group — Grievances and Appeals – Oregon
Introduced: Status: Enacted
Provides the process for appeal and external review. Requires an insurer to provide all information relating to benefit design and provider networks. States that an insurer must have an external review program to assess whether […]
Download
Or. Rev. Stat. § 743A.082. Diabetes management for pregnant women: Health Insurance: Reimbursement of Claims – Oregon
Introduced: Status: Enacted
States that a health benefit plan may not require a copayment or impose a coinsurance requirement or deductible on the covered services, medications and supplies that are medically necessary for a woman to manage her […]
Download
Or. Rev. Stat. §§ 743.028 through 743.035: Health and Life Insurance — General Provisions (Forms and Standards) – Oregon
Introduced: Status: Enacted
The Department of Consumer and Business Services, in consultation with the Oregon Health Authority, shall develop by rule a form that providers in this state shall use to request prior authorization for prescription drug benefits.
Download
Or. Rev. Stat. § 678.390. Authority of nurse practitioner and clinical nurse specialist to write prescriptions or dispense drugs; notice; requirements; revocation; rules: Professional Nurses (Prescriptive Authority) – Oregon
Introduced: Status: Enacted
The Oregon State Board of Nursing may authorize a certified nurse practitioner or certified clinical nurse specialist to write prescriptions, including prescriptions for controlled substances listed in schedules II, III, III N, IV and V.
Download
Next | See all Legislation Records
Federal Trade Commission v. Actavis, Inc. – Georgia
District Court: Northern District of Georgia Status: Decided
The Supreme Court ruled in favor of the FTC, holding that a brand name manufacturer’s payment to a generic competitor to settle patent infringement claims […]
Federal Trade Commission v. Shire ViroPharma Inc. – Delaware
District Court: District of Delaware Status: Decided
On February 7, 2017, the FTC filed a complaint against Shire ViroPharma, alleging that the pharmaceutical company engaged in unfair method of competition and violated […]
Walgreen Co. et al v. Allergan, Inc – New York
District Court: Eastern District of New York Status: Pending
Four drug retailers, including Walgreens and Albertsons, filed an antitrust suit alleging that Allergan devised and carried out a multifaceted and anticompetitive scheme to maintain […]
PhRMA v. David – California
District Court: Eastern District of California Status: Decided
PhRMA challenged California’s drug price transparency law SB 17 alleging that the law is unconstitutional because it violates the Commerce Clause, the First Amendment, and […]
Pharmaceutical Care Management Association (PCMA) v. Rutledge – Arkansas
District Court: Eastern District of Arkansas Status: Decided
Act 900 (SB 688), enacted in 2015, required disclosure of generic drug pricing and sets a floor on prices that PBMs can pay to pharmacies […]
In re Express Scripts/Anthem ERISA Litigation – New York
District Court: Southern District of New York Status: Pending
The district court dismissed a proposed class action against Anthem Inc. and Express Scripts Inc. over drug pricing methods, holding that the companies can’t be […]
Alcon Labs., Inc. v. Cottrell – New Jersey
District Court: District of New Jersey Status: Decided
Consumers brought putative class action against manufacturers and distributors of prescription eye medication, alleging they packaged medication in such a way as to force consumers […]
Previous | Next | See all Litigation Records
District Court: Northern District of Georgia Status: Decided
The Supreme Court ruled in favor of the FTC, holding that a brand name manufacturer’s payment to a generic competitor to settle patent infringement claims […]
Federal Trade Commission v. Shire ViroPharma Inc. – Delaware
District Court: District of Delaware Status: Decided
On February 7, 2017, the FTC filed a complaint against Shire ViroPharma, alleging that the pharmaceutical company engaged in unfair method of competition and violated […]
Walgreen Co. et al v. Allergan, Inc – New York
District Court: Eastern District of New York Status: Pending
Four drug retailers, including Walgreens and Albertsons, filed an antitrust suit alleging that Allergan devised and carried out a multifaceted and anticompetitive scheme to maintain […]
PhRMA v. David – California
District Court: Eastern District of California Status: Decided
PhRMA challenged California’s drug price transparency law SB 17 alleging that the law is unconstitutional because it violates the Commerce Clause, the First Amendment, and […]
Pharmaceutical Care Management Association (PCMA) v. Rutledge – Arkansas
District Court: Eastern District of Arkansas Status: Decided
Act 900 (SB 688), enacted in 2015, required disclosure of generic drug pricing and sets a floor on prices that PBMs can pay to pharmacies […]
In re Express Scripts/Anthem ERISA Litigation – New York
District Court: Southern District of New York Status: Pending
The district court dismissed a proposed class action against Anthem Inc. and Express Scripts Inc. over drug pricing methods, holding that the companies can’t be […]
Alcon Labs., Inc. v. Cottrell – New Jersey
District Court: District of New Jersey Status: Decided
Consumers brought putative class action against manufacturers and distributors of prescription eye medication, alleging they packaged medication in such a way as to force consumers […]
Previous | Next | See all Litigation Records
News & Opinions
Articles & Reports
JAMA Network
April 6, 2026
Health Affairs April 6, 2026
Health Affairs April 6, 2026
Health Affairs Forefront March 23, 2026
Health Affairs April 6, 2026
Health Affairs April 6, 2026
Health Affairs Forefront March 23, 2026
Trends in Pharmaceuticals
2019 Pharmaceutical Legislation
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2019 session.
-
Key:
- Enacted
- Considered
- No Legislative Session
Price Transparency
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2018 session.
-
Key:
- Enacted
- Considered
- No Legislative Session
Rate Setting
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2018 session.
-
Key:
- Enacted
- Considered
- No Legislative Session
Price Gouging
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2018 session.
-
Key:
- Enacted
- Considered
- No Legislative Session
Drug Importation
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2018 session.
-
Key:
- Enacted
- Considered
- No Legislative Session
Pharmacy Gag Clause Regulation
Gag clause regulation includes laws that allow pharmacists to disclose costs to insured patients and those that prohibit pharmacists from collecting more in cost-sharing from the insured patient than the cash price. See The Source’s Spotlight on 2018 State Drug Legislation Part 3 and 2018 legislation chart for more information.
-
Key:
- Enacted
- Considered
- No Legislative Session
PBM Regulation
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2018 session.
-
Key:
- Enacted
- Considered
- No Legislative Session
Pharma Other
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2018 session.
-
Key:
- Enacted
- Considered
- No Legislative Session